Diffusion Pharmaceuticals Valuation
| DFFNDelisted Stock | USD 3.27 0.17 5.48% |
At this time, the firm appears to be overvalued. Diffusion Pharmaceuticals shows a prevailing Real Value of $2.89 per share. The current price of the firm is $3.27. Our model computes the value of Diffusion Pharmaceuticals from reviewing the firm fundamentals such as Current Valuation of (6.02 M), shares owned by insiders of 0.23 %, and Shares Owned By Institutions of 10.27 % as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Diffusion Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Diffusion Pharmaceuticals is based on 3 months time horizon. Increasing Diffusion Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Diffusion Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Diffusion Stock. However, Diffusion Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.27 | Real 2.89 | Hype 3.27 | Naive 3.42 |
The intrinsic value of Diffusion Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Diffusion Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Diffusion Pharmaceuticals helps investors to forecast how Diffusion stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Diffusion Pharmaceuticals more accurately as focusing exclusively on Diffusion Pharmaceuticals' fundamentals will not take into account other important factors: Diffusion Pharmaceuticals Total Value Analysis
Diffusion Pharmaceuticals is currently forecasted to have valuation of (6.02 M) with market capitalization of 8.98 M, debt of 67.89 K, and cash on hands of 25.86 M. The negative valuation of Diffusion Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Diffusion Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(6.02 M) | 8.98 M | 67.89 K | 25.86 M |
Diffusion Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Diffusion is to check how much profit was generated for every dollar of assets it reports. Diffusion Pharmaceuticals shows a negative utilization of assets of -0.38 percent, losing $0.003824 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Diffusion Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Diffusion Pharmaceuticals Ownership Allocation
Roughly 89.5 percent of Diffusion Pharmaceuticals outstanding shares are held by general public with 0.23 (percent) owned by insiders and only 10.27 % by other corporate entities.Diffusion Pharmaceuticals Profitability Analysis
Net Loss for the year was (15.59 M) with profit before overhead, payroll, taxes, and interest of 0.About Diffusion Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Diffusion Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Diffusion Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Diffusion Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Diffusion Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Diffusion Pharmaceuticals. We calculate exposure to Diffusion Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Diffusion Pharmaceuticals's related companies.Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the bodys ability to deliver oxygen. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia. Diffusion Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.
Diffusion Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 2 M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Diffusion Stock
If you are still planning to invest in Diffusion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Diffusion Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |